A randomized trial assessing the utility of a test-dose program with taxanes

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Taxanes are vital chemotherapy drugs frequently associated with hypersensitivity reactions (HSRs).
• Managing HSRs is crucial for patient safety and treatment continuity.

Purpose of the Study:

• To assess the clinical and economic impact of a pre-medication test dose for taxane chemotherapy.
• To evaluate if a small intravenous test dose reduces the incidence and severity of HSRs to paclitaxel or docetaxel.

Main Methods:

• A randomized controlled trial involving 218 patients receiving either a full dose or a 1 mg intravenous test dose of paclitaxel or docetaxel.
• Primary endpoints included HSR severity and the cost of drug wastage attributed to HSRs.

Main Results:

• The overall HSR incidence was 6.5%, with no statistically significant difference between the test dose and full dose groups.
• Mean HSR severity grade was slightly lower in the test dose group (2.3) compared to the full dose group (2.8).
• Significant cost savings were observed, with $1573 per HSR patient and $104 per treated patient in avoided taxane wastage within the test dose arm.

Conclusions:

• A pre-medication test dose of taxanes does not appear to mitigate the severity of hypersensitivity reactions.
• The strategy of administering a test dose effectively reduces the economic burden associated with taxane drug wastage during HSRs.